Kuanping Capital
Overview
Kuanping Capital is a Shanghai-based private equity firm specializing in healthcare-focused investments across China. The firm concentrates on sectors such as biotech, healthcare, consumer goods, and technology, aiming to support innovative companies in these industries. Established in 2016, Kuanping Capital employs a research-based, strategy-oriented approach to active investments. The firm partners with outstanding entrepreneurs to achieve superior returns through value creation, focusing on early-stage, growth, and late-stage investments. Kuanping Capital has demonstrated its commitment to the healthcare sector by leading significant funding rounds, such as the over $20 million Series B+ financing for Brattea, a leading renal denervation company in China. This investment underscores the firm's dedication to advancing medical technologies and improving patient outcomes.
Investment Focus
- Focus on healthcare, biotech, consumer goods, and technology sectors
- Preference for early-stage to late-stage companies with innovative solutions
- Alignment with Kuanping Capital's strategic investment approach
Portfolio Companies
Reach Kuanping Capital directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Kuanping Capital
What sectors does Kuanping Capital invest in?
Kuanping Capital invests in Technology, Healthcare, Consumer Goods and Biotech, and is based in China. Kuanping Capital is listed as a private equity in the ConnectSafely investor database.
What stage does Kuanping Capital invest at?
Kuanping Capital backs companies at Early Stage, Growth and Late Stage.
Which regions does Kuanping Capital invest in?
Kuanping Capital invests across China.
What companies has Kuanping Capital invested in?
Kuanping Capital's portfolio includes Brattea.
Last updated · Source: ConnectSafely investor database
